Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for SIMCERE PHARMA?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2017–2025
Financial statements are reported in CNY, while share price and market cap are quoted in HKD.
Key Multi-Year Facts
- Revenue moved from CN¥3.87B in FY2017 to CN¥7.73B in FY2025 (8-year CAGR +9.0%).
- Profitable in every fiscal year across 2017–2025.
- Operating cash flow was below half of net income in FY2020, FY2021, FY2023.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (CNY B) | 5.00 | 6.32 | 6.61 | 6.64 | 7.73 |
| YoY | 10.9% | 26.5% | 4.5% | 0.4% | 16.5% |
| Net Income (CNY B) | 1.51 | 0.93 | 0.71 | 0.72 | 1.34 |
| YoY | 125.1% | -38.2% | -23.2% | 1.0% | 86.2% |
| Operating Cash Flow (CNY B) | -0.20 | 1.35 | 0.15 | 1.39 | 2.01 |
| ROE | 23.4% | 13.7% | 10.0% | 10.1% | 16.2% |
| Gross Margin | 78.4% | 79.0% | 75.4% | 80.2% | 81.6% |
| Net Margin | 30.1% | 14.7% | 10.8% | 10.9% | 17.4% |
| Debt-to-Assets | 36.4% | 33.7% | 33.5% | 38.5% | 36.1% |
Show all 9 fiscal years
| Fiscal Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (CNY B) | 3.87 | 4.51 | 5.04 | 4.51 | 5.00 | 6.32 | 6.61 | 6.64 | 7.73 |
| YoY | — | 16.7% | 11.6% | -10.5% | 10.9% | 26.5% | 4.5% | 0.4% | 16.5% |
| Net Income (CNY B) | 0.35 | 0.73 | 1.00 | 0.67 | 1.51 | 0.93 | 0.71 | 0.72 | 1.34 |
| YoY | — | 109.4% | 36.8% | -33.3% | 125.1% | -38.2% | -23.2% | 1.0% | 86.2% |
| Operating Cash Flow (CNY B) | 0.94 | 0.78 | 0.77 | 0.10 | -0.20 | 1.35 | 0.15 | 1.39 | 2.01 |
| ROE | 19.7% | 43.9% | 65.9% | — | 23.4% | 13.7% | 10.0% | 10.1% | 16.2% |
| Gross Margin | 84.8% | 82.9% | 82.4% | 80.0% | 78.4% | 79.0% | 75.4% | 80.2% | 81.6% |
| Net Margin | 9.1% | 16.3% | 19.9% | 14.8% | 30.1% | 14.7% | 10.8% | 10.9% | 17.4% |
| Debt-to-Assets | 65.7% | 75.3% | 78.1% | — | 36.4% | 33.7% | 33.5% | 38.5% | 36.1% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
-
Watch
Profit WarningMaterial Events
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
Trailing 12-month dividend: HK$0.209 per share, or 1.94% yield at closing price; last full fiscal year: HK$0.209 (payout ratio 30.1%).
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.